Close Menu

NEW YORK (GenomeWeb) – Ginkgo Bioworks today announced it has acquired several assets from Warp Drive Bio, a subsidiary of Revolution Medicines, including its genome mining platform.

Warp Drive's bioinformatics technology sifts through microbial genome databases to uncover potential antibiotics. Its genomic database includes more than 135,000 bacterial strains.

Under the terms of the deal, Ginkgo will obtain Warp Drive's genomic sequence collection and bioinformatics software. Warp Drive's genome mining team will also move to Ginkgo's headquarters in Boston.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Sponsored by

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.